How safe and manageable is a new intravenous immunoglobulin therapy in adults living with primary immunodeficiency?

This plain language summary reflects the content of the following scientific abstract: 'safety and tolerability of a new intravenous immunoglobulin (IVIg) 10% in primary immunodeficiency (PI) adult patients,' presented at the 2025 Clinical Immunology Society Annual Meeting: Immune Deficiency & Dysregulation North American Conference (Philadelphia, PA, USA; May 1–4, 2025). For more information on the study, please visit: https://clinconnect.io/trials/NCT01581593

The purpose of this plain language summary is to help you to understand the findings from recent research. This summary reports the results of a single study. The results of the study may differ from those of other studies. Health professionals should make treatment decisions based on all available evidence, not on the results of a single study.

Writing and editorial support for this summary was provided by Alison Halliday, PhD, Lauri Arnstein Williams, MA, MBBS, Simon Stones, PhD, ISMPP CMPP™, and Sam Leeves, BA, at Amica Scientific, and funded by Kedrion Biopharma, Inc. The original authors of the scientific abstract were involved in reviewing this summary.